At least two months before you plan to become pregnant. Tirzepatide has a half-life of approximately five days, meaning it takes roughly 30 days for the drug to clear your system after the last injection [1]. The two-month recommendation builds in a safety margin beyond that pharmacokinetic clearance — because animal studies showed fetal growth reductions and structural abnormalities at clinically relevant exposures, and there are essentially no human pregnancy data to fall back on [1]. If you're on Mounjaro or Zepbound and pregnancy is anywhere on your horizon, the conversation about timing needs to start well before you stop contraception.

Why the Washout Period Matters

Tirzepatide is classified as FDA pregnancy category "not formally assigned" — the agency uses a narrative risk statement instead. The prescribing information states directly: "Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy. MOUNJARO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus" [1].

The animal data is what drives the caution. In pregnant rats given tirzepatide during organogenesis — the critical period when fetal organs form — researchers observed increased incidences of external, visceral, and skeletal malformations, along with decreased fetal weights, at exposures comparable to human therapeutic doses [1]. In pregnant rabbits, fetal growth reductions occurred at clinically relevant exposures. These effects coincided with reduced maternal body weight and food consumption — which means the fetal harm may be partly mediated by the drug's intended weight-loss effect rather than direct toxicity, but that distinction doesn't make the risk less real.

The honest summary: we don't know whether tirzepatide causes birth defects in humans. No adequate studies exist. What we know is that it causes problems in animals at doses comparable to what humans take, and that the prudent course is to have it fully out of your system before conception.

The Pharmacokinetics: Why Two Months, Not Two Weeks

Tirzepatide's elimination half-life is approximately five days [1]. In pharmacology, it takes roughly five half-lives for a drug to be considered effectively eliminated from the body. For tirzepatide, that's approximately 25-30 days.

The MotherToBaby fact sheet — published by the Organization of Teratology Information Specialists through the NCBI Bookshelf — states that "in healthy adults, it can take up to 30 days, on average, for most of the tirzepatide to be gone from the body" [2].

So why two months rather than one? Three reasons:

• Individual variation matters. Thirty days is an average. Some people metabolize the drug more slowly, particularly those with higher body weight, reduced kidney function, or other factors that affect clearance. A two-month window accommodates slower eliminators.
• Conception timing is imprecise. You don't conceive the day you decide to try. Ovulation timing varies, and the most critical period for fetal development — the first few weeks after conception — often occurs before a pregnancy test turns positive. A longer washout protects against that gap.
• The risk window is earliest pregnancy. Organogenesis occurs during weeks 3-8 of pregnancy, often before many women know they're pregnant. Having the drug fully cleared before conception means the highest-risk developmental period is protected even if pregnancy happens sooner than planned.

For comparison, semaglutide (Ozempic, Wegovy) has a longer half-life of approximately seven days, taking up to six weeks to clear. The Wegovy prescribing information explicitly states: "Discontinue WEGOVY in patients at least 2 months before a planned pregnancy" [3]. Tirzepatide's own label doesn't include this specific pre-conception timeline — the Mounjaro label focuses on discontinuing when pregnancy is recognized — but most clinicians apply the same two-month standard or longer, given the comparable pharmacokinetic profile and similar animal findings.

What the FDA Labels Say — and Don't Say

This is an area where the prescribing information creates confusion rather than resolving it.

The Mounjaro label (2022) states that tirzepatide "should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus" [1]. It details the animal study findings but does not specify a pre-conception washout timeline. It does not tell you how long before trying to conceive you should stop.

The Wegovy label (semaglutide) is more explicit: "Discontinue WEGOVY in patients at least 2 months before a planned pregnancy" [3]. This is the clearest guidance from any GLP-1 or GIP receptor agonist label.

The Zepbound label (tirzepatide for obesity, 2025) similarly advises that weight loss is not recommended during pregnancy and to discontinue when pregnancy is recognized [4]. Like the Mounjaro label, it does not specify a pre-conception washout period.

The practical guidance most reproductive endocrinologists and obesity medicine specialists follow: apply the two-month minimum from the Wegovy label to tirzepatide as well, since the pharmacokinetic profiles are comparable and the animal safety signals are similar. Some providers recommend longer — up to three months — for patients with higher BMI or renal impairment, where drug clearance may be slower.

The "Ozempic Babies" Phenomenon — and Why It Changes This Conversation

One of the most significant developments in GLP-1 medicine has been the wave of unplanned pregnancies in women taking these medications — a phenomenon widely covered under the term "Ozempic babies."

The mechanism is straightforward. Obesity disrupts ovulation through multiple pathways: excess adipose tissue produces abnormal levels of estrogen, insulin resistance interferes with reproductive hormones, and conditions like polycystic ovary syndrome (PCOS) — which affects approximately 7-10% of women of reproductive age — further impair fertility [5]. When women lose significant weight on GLP-1 medications, these hormonal disruptions can reverse rapidly. Ovulation resumes, often without warning. Women who were told they couldn't conceive, or who had years of failed fertility treatments, suddenly find themselves pregnant.

A review of studies involving 840 women with PCOS across 11 randomized controlled trials found that GLP-1 use was associated with improved rates of spontaneous pregnancy [5]. The SELECT trial reported that 44% of patients on semaglutide lost more than 10% of their body weight within two years — a threshold at which fertility-related hormonal changes become clinically significant [5].

This means two things for women on tirzepatide who may want to become pregnant in the future:

First, fertility can return before you expect it. If you've been told you're unlikely to conceive due to PCOS or obesity-related anovulation, tirzepatide-driven weight loss can change that equation — sometimes within months of starting treatment. Don't assume prior infertility is still protective.

Second, the oral contraceptive interaction makes this worse. Tirzepatide reduces peak hormone levels of oral contraceptives by 55-66%, with overall drug exposure (AUC) reduced by approximately 20-23% — still clinically significant enough to warrant concern about contraceptive reliability [1]. If you're relying on oral contraceptives while taking a drug that both restores your fertility and reduces your contraceptive protection, the risk of unplanned pregnancy compounds.

The Oral Contraceptive Complication

Tirzepatide slows gastric emptying, which changes how oral medications are absorbed. For birth control pills, the FDA studied this interaction directly: peak blood levels (Cmax) of ethinyl estradiol dropped by 59%, norgestimate by 66%, and its active metabolite norelgestromin by 55% when taken alongside tirzepatide [1]. However, total drug exposure over time (AUC) — which is more clinically relevant for sustained contraceptive efficacy — decreased by a smaller margin of approximately 20-23%. The peak level reduction is real and drives the label warning, but the overall absorption picture is less dramatic than the Cmax numbers alone suggest.

The label advises using backup contraception or switching to a non-oral method for four weeks after starting tirzepatide and four weeks after each dose increase [1]. But here's the practical problem: during a multi-month titration from 2.5 mg up through 15 mg, those four-week windows overlap continuously. You may need backup contraception for the entire titration period.

Non-oral methods are unaffected. IUDs, implants (Nexplanon), injectable contraception (Depo-Provera), patches, and vaginal rings all bypass the GI tract and are not impacted by delayed gastric emptying [1]. If you're on tirzepatide and not ready to conceive, switching to a non-oral method eliminates both the absorption interaction and the coordination burden of tracking backup windows.

This interaction is specific to tirzepatide. Semaglutide does not produce a clinically meaningful effect on oral contraceptive absorption — multiple studies have confirmed this [6]. The difference is likely due to tirzepatide's dual GLP-1/GIP mechanism producing a stronger effect on gastric emptying than pure GLP-1 agonists.

Planning the Transition: A Practical Timeline

If you're on tirzepatide and planning pregnancy, the transition involves more than just stopping a medication.

6+ months before trying to conceive:

• Discuss the plan with your provider. Ideally, this conversation happens early — not the month you want to start trying. Your clinician needs to plan for how to manage weight stability after discontinuation, adjust any other medications, and ensure your metabolic health is optimized for pregnancy.
• Switch contraception if needed. If you're on oral contraceptives, switch to a non-oral method now. This removes the absorption interaction and gives you reliable contraception during the transition period.
• Optimize nutrition and body composition. Pregnancy increases nutritional demands. Ensuring adequate folate, iron, and protein stores before conception — while you still have the appetite suppression to make dietary changes easier — is strategic.

2-3 months before trying to conceive:

• Take your last dose of tirzepatide. This allows approximately two months of clearance time. Your provider may recommend a gradual taper rather than abrupt cessation to manage appetite rebound and weight stability.
• Start prenatal vitamins if you haven't already. Folate supplementation should begin at least one month before conception to prevent neural tube defects.
• Baseline labs. Kidney function, thyroid, HbA1c (if diabetic), and a general metabolic panel establish your pre-pregnancy health status.

During the washout period:

• Expect appetite changes. When tirzepatide leaves your system, the appetite suppression and "food noise" quieting will diminish. This is the period when the habits you built during treatment matter most.
• Monitor weight, but don't panic. Some weight fluctuation after stopping is normal and doesn't necessarily indicate fat regain — fluid shifts and increased food volume in the GI tract account for early changes.
• Continue contraception until you've completed the full washout and are ready to conceive. The two-month clock starts from your last injection, not from when you decided to stop.

What Your Provider Should Be Discussing

This is a conversation that too often doesn't happen — or happens too late. A provider prescribing tirzepatide to a woman of reproductive age should be addressing pregnancy planning from the first appointment, not when a patient mentions she might want to start trying next month.

JumpstartMD integrates this into their clinical framework from the outset. Pregnancy is part of the contraindication screening before the first dose — not as a checkbox, but as an ongoing clinical consideration. GLP-1 medications should typically be stopped well in advance of planned pregnancy due to their long half-lives, and the clinical team addresses this proactively rather than reactively. For patients on tirzepatide specifically, the oral contraceptive interaction is discussed at initiation and revisited at each dose escalation, because the four-week backup window resets every time.

The broader medication reconciliation matters here too. If you're on other medications that affect fertility or pregnancy — metformin for PCOS, blood pressure medications that are contraindicated in pregnancy (ACE inhibitors, ARBs), thyroid medications that need dose adjustment — all of these require coordinated planning. A provider who sees you only for the GLP-1 prescription and doesn't know your full medication picture can't coordinate this transition safely.

The specific details your provider needs before you begin planning:

• Your current contraceptive method and whether it's affected by tirzepatide's gastric emptying delay
• Your full medication list — some medications need to be stopped or switched before conception (not just tirzepatide)
• Your metabolic baseline — HbA1c, kidney function, thyroid levels, blood pressure — because pregnancy will change all of these
• Your body composition trajectory — whether you've preserved adequate lean mass during weight loss, since muscle mass affects metabolic stability during the transition off medication
• Your weight stability plan — how you'll maintain results after discontinuation, which requires the behavioral and nutritional foundation built during treatment

At JumpstartMD, this planning happens within the ongoing clinical relationship — not as a rushed conversation at the last appointment before discontinuation. The care team coordinates with patients' OB-GYNs and reproductive endocrinologists when needed, ensuring the transition from weight management to pregnancy planning is medically supervised from both sides. Call 408.478.3496 to discuss your specific situation.

Frequently Asked Questions

Q: Can I get pregnant while still taking tirzepatide? A: Pregnancy can occur on tirzepatide — and it's happening more often than expected. Weight loss can restore ovulation in women with PCOS or obesity-related anovulation, sometimes within months of starting treatment. Combined with tirzepatide's reduction of oral contraceptive effectiveness, unplanned pregnancy is a real risk. If you become pregnant while taking tirzepatide, stop the medication and contact your provider immediately.

Q: Is the two-month washout the same for semaglutide? A: Yes. The Wegovy prescribing information explicitly states: "Discontinue WEGOVY in patients at least 2 months before a planned pregnancy" [3]. Semaglutide actually has a longer half-life than tirzepatide (seven days versus five days), so the clearance time is slightly longer — approximately six weeks. The two-month recommendation applies to both medications.

Q: What if I discover I'm pregnant while still on tirzepatide? A: Stop tirzepatide immediately and contact your provider. A 2023 observational study of approximately 50,000 pregnant women with type 2 diabetes found no statistically significant increase in major birth defects among the 900+ women who were taking GLP-1 receptor agonists when they learned they were pregnant [5]. This is reassuring but limited — the data is observational, not from controlled trials, and most exposures occurred in early pregnancy before the drug was discontinued.

Q: Does tirzepatide affect male fertility? A: No changes in male fertility were reported in animal studies [2]. Studies have not been done in humans, but in general, paternal medication exposures are unlikely to increase risks to a pregnancy. The two-month washout recommendation applies to the person who will be pregnant, not the partner.

Q: Should I taper off tirzepatide or stop abruptly before trying to conceive? A: Discuss this with your provider. Abrupt cessation means a faster start to the two-month clearance clock, but it also means a more sudden return of appetite and potential weight instability. Some clinicians prefer a brief taper — stepping down one or two dose levels over a few weeks — before the final stop, to ease the metabolic transition. Either way, the two-month clock starts from the last injection at any dose.

Q: Does JumpstartMD help patients plan for pregnancy while on GLP-1 treatment? A: Yes. JumpstartMD screens for pregnancy planning from the initial consultation and addresses contraception, including the tirzepatide-specific oral contraceptive interaction, at every dose change. When a patient begins planning for conception, the clinical team coordinates the medication transition — including taper strategy, nutritional optimization, and body composition monitoring — and works with the patient's OB-GYN or reproductive endocrinologist as needed. Call 408.478.3496 to discuss your situation.

Conclusion

Stop tirzepatide at least two months before trying to conceive. The drug takes approximately 30 days to clear your system, and the extra margin accounts for individual variation, the imprecision of conception timing, and the critical early weeks of fetal development when organogenesis occurs [1][2]. Animal studies show fetal harm at human-equivalent doses, and there is insufficient human data to rule out risk. If you're on tirzepatide and pregnancy is in your future — even distantly — make sure your provider knows, and plan the transition early enough that the washout, contraceptive management, and metabolic stabilization happen on your timeline, not as an emergency.

References

[1] U.S. Food and Drug Administration, "Highlights of prescribing information: Mounjaro (tirzepatide) injection, for subcutaneous use," 2022. [Accessed: Feb. 11, 2026].

[2] Organization of Teratology Information Specialists, "Tirzepatide (Mounjaro, Zepbound) — MotherToBaby Fact Sheet," NCBI Bookshelf, 2024. [Accessed: Feb. 11, 2026].

[3] U.S. Food and Drug Administration, "Highlights of prescribing information: Wegovy (semaglutide) injection, for subcutaneous use," 2024. [Accessed: Feb. 11, 2026].

[4] U.S. Food and Drug Administration, "Highlights of prescribing information: Zepbound (tirzepatide) injection, for subcutaneous use," 2025. [Accessed: Feb. 11, 2026].

[5] UT Southwestern Medical Center, "Surprise 'Ozempic babies' underscore links between obesity and fertility," 2024. [Accessed: Feb. 11, 2026].

[6] A. N. Nguyen et al., "The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception," Journal of the American Pharmacists Association, 2023. [Accessed: Feb. 11, 2026].